InflaRx (IFRX) FCF Payout Ratio (2016 - 2026)

InflaRx (IFRX) posted FCF Payout Ratio of 2.03 for Q1 2026, down 4.68% sequentially from 1.94 in Q4 2025, and up 39.85% YoY from 1.45 in Q1 2025.

InflaRx (IFRX) FCF Payout Ratio (2016 - 2026) Analysis & Trends

InflaRx has reported FCF Payout Ratio for 11 years, with the latest figure at 2.03 in Q1 2026.

Quarterly FCF Payout Ratio rose 39.85% year-over-year to 2.03 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.53 (up 163.79% YoY) and the FY2025 annual result came in at 0.45, down 19.61% from the prior year.
FCF Payout Ratio declined to 2.03 in Q1 2026 per IFRX's latest filing, from 1.94 in the prior quarter.
Over five years, FCF Payout Ratio peaked at 4.55 in Q2 2025 and troughed at 3.38 in Q1 2025.
A 5-year average of 0.37 and a median of 0.42 in 2023 frame the typical range for FCF Payout Ratio.
The sharpest annual moves came in 2024 and 2025: FCF Payout Ratio tumbled 747.02% in 2024, then surged 826.45% in 2025.
Over 5 years, FCF Payout Ratio stood at 0.34 in 2022, then surged by 140.33% to 0.81 in 2023, then decreased by 19.4% to 0.65 in 2024, then sank by 396.63% to 1.94 in 2025, then retreated by 4.68% to 2.03 in 2026.
According to Business Quant data, FCF Payout Ratio over the past three periods registered 2.03, 1.94, and 0.73 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.17
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.07
10	InflaRx	140.30 Mn	-43.96 Mn	2.74 Bn	-51.89

Download Data